Mesothelioma is a rare but aggressive cancer caused by asbestos exposure. Treatment options have advanced in recent years, offering more hope for those diagnosed. New therapies focus on improving survival rates and quality of life.
Immunotherapy advancements
Immunotherapy is changing how mesothelioma is treated. Drugs like nivolumab and pembrolizumab help the immune system fight cancer cells more effectively. These medications, called checkpoint inhibitors, block proteins that allow cancer to grow unchecked. Some patients respond well, experiencing longer survival times with fewer side effects than traditional chemotherapy.
Targeted therapy options
Targeted therapy focuses on specific genetic mutations in mesothelioma cells. Drugs like bevacizumab target blood vessel growth in tumors, cutting off their nutrient supply. Other treatments focus on blocking signals that help cancer cells multiply. While still being studied, targeted therapy offers a more personalized approach to treatment.
Multimodal treatment approaches
Doctors often combine treatments for better results. Surgery, chemotherapy, and radiation therapy work together to slow cancer progression. Some patients receive heated intraperitoneal chemotherapy (HIPEC) after surgery, which delivers cancer-killing drugs directly to affected areas. This approach helps destroy remaining cancer cells while minimizing harm to healthy tissues.
Emerging clinical trials
Clinical trials continue to test new drugs and treatment methods. Gene therapy, tumor-treating fields, and combination therapies are being explored for their effectiveness. Patients may benefit from participating in trials, as they provide access to cutting-edge treatments before they become widely available.
Hope for the future
Advancements in mesothelioma treatment are offering better options than ever before. While no cure exists yet, new therapies are improving outcomes and quality of life. Staying informed about the latest treatments and clinical trials can help patients and their families make the best decisions for their care.